Tens of millions worldwide taking Ozempic and similar GLP-1 drugs have created an unprecedented real-world experiment, revealing effects that clinical trials couldn't capture. Doctors report patients lost 15-20% body weight in trials, but real-world results vary widely from 8-17%, partly because many discontinue treatment due to side effects or costs.

About 10% of users are 'non-responders' losing less than 5% weight, while others regain pounds after stopping. Some maintain losses through exercise, surgery, or alternative medications. The dosing debate intensifies as higher doses yield more weight loss but may push patients to unhealthy weights, risking nutritional deficiencies, bone density loss, and gallstones.

Unexpected side effects include 'Ozempic breath,' facial hollowing, and hair loss, with rare links to eye conditions and pancreatitis. Patients frequently lose muscle mass, particularly older adults becoming frail. These findings directly impact pharmaceutical companies' liability exposure and treatment protocols.

Users report changed sex lives and diminished pleasure from eating, with some feeling emotionally flatter or experiencing personality dulling. These mental health impacts could reshape insurance coverage and prescribing patterns as the market grapples with long-term safety versus short-term weight loss benefits.